Tumor Suppressor PTPRJ Is a Target of miR-155 in Colorectal Cancer

Journal of Cellular Biochemistry

Volumn 118, Issue 10, 2017, Pages 3391-3400

  Zhang, Xiao Fei ^a   Tu, Rongfu ^b   Li, Keke ^b   Ye, Pengxiang ^a   Cui, Xiaofeng ^a  

^a WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

COLORECTAL CANCER; microRNA 155; PTPRJ

Indexed keywords

GENOMIC DNA; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN G; MICRORNA 155; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR J; UNCLASSIFIED DRUG; VASCULOTROPIN; MICRORNA; MIRN155 MICRORNA, HUMAN; PTPRJ PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; RNA; TUMOR SUPPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; ECTOPIC EXPRESSION; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HCT 116 CELL LINE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEINS;

EID: 85018979823     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25995     Document Type: Article

References (47)

1. Arlt A, Bauer I, Schafmayer C, Tepel J, Muerkoster SS, Brosch M, Roder C, Kalthoff H, Hampe J, Moyer MP, Folsch UR, Schafer H. 2009. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 28(45):3983–3996.
2. Arora D, Stopp S, Bohmer SA, Schons J, Godfrey R, Masson K, Razumovskaya E, Ronnstrand L, Tanzer S, Bauer R, Bohmer FD, Muller JP. 2011. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J Biol Chem 286(13):10918–10929.
3. Balavenkatraman KK, Jandt E, Friedrich K, Kautenburger T, Pool-Zobel BL, Ostman A, Bohmer FD. 2006. DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients. Oncogene 25(47):6319–6324.
4. Brenner H, Kloor M, Pox CP. 2014. Colorectal cancer. Lancet 383(9927):1490–1502.
5. Cekaite L, Eide PW, Lind GE, Skotheim RI, Lothe RA. 2015. MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget 7(6):6476–6505.
6. Dave RK, Dinger ME, Andrew M, Askarian-Amiri M, Hume DA, Kellie S. 2013a. Regulated expression of PTPRJ/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli. PLoS ONE 8(6):e68306.
7. Dave RK, Naylor AJ, Young SP, Bayley R, Hardie DL, Haworth O, Rider DA, Cook AD, Buckley CD, Kellie S. 2013b. Differential expression of CD148 on leukocyte subsets in inflammatory arthritis. Arthritis Res Ther 15(5):R108.
8. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. 2014. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–271.
9. Dews M, Fox JL, Hultine S, Sundaram P, Wang W, Liu YY, Furth E, Enders GH, El-Deiry W, Schelter JM, Cleary MA, Thomas-Tikhonenko A. 2010. The myc-miR-17 ∼ 92 axis blunts TGFβ signaling and production of multiple TGFβ-dependent antiangiogenic factors. Cancer Res 70(20):8233–8246.
10. Feng Z, Xia Y, Zhang M, Zheng J. 2013. MicroRNA-155 regulates T cell proliferation through targeting GSK3beta in cardiac allograft rejection in a murine transplantation model. Cell Immunol 281(2):141–149.
11. Fong EL, Harrington DA, Farach-Carson MC, Yu H. 2016. Heralding a new paradigm in 3D tumor modeling. Biomaterials 108:197–213.
12. Fournier P, Dussault S, Fusco A, Rivard A, Royal I. 2016. Tyrosine phosphatase PTPRJ/DEP-1 Is an essential promoter of vascular permeability, angiogenesis, and tumor progression. Cancer Res 76(17):5080–5091.
13. Friedman RC, Farh KK, Burge CB, Bartel DP. 2009. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105.
14. Huang X, Shen Y, Liu M, Bi C, Jiang C, Iqbal J, McKeithan TW, Chan WC, Ding SJ, Fu K. 2012. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol 181(1):26–33.
15. Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A. 2006. The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 66(12):6280–6287.
16. Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano M. 2016. Control of the inflammatory macrophage transcriptional signature by miR-155. PLoS ONE 11(7):e0159724.
17. Katsumoto TR, Kudo M, Chen C, Sundaram A, Callahan EC, Zhu JW, Lin J, Rosen CE, Manz BN, Lee JW, Matthay MA, Huang X, Sheppard D, Weiss A. 2013. The phosphatase CD148 promotes airway hyperresponsiveness through SRC family kinases. J Clin Invest 123(5):2037–2048.
18. Keane MM, Lowrey GA, Ettenberg SA, Dayton MA, Lipkowitz S. 1996. The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. Cancer Res 56(18):4236–4243.
19. Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature 405(6785):421–424.
20. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. Dev Cell 11(4):441–450.
21. Kutty RK, Nagineni CN, Samuel W, Vijayasarathy C, Hooks JJ, Redmond TM. 2010. Inflammatory cytokines regulate microRNA-155 expression in human retinal pigment epithelial cells by activating JAK/STAT pathway. Biochem Biophys Res Commun 402(2):390–395.
22. Luo X, Yang S, Zhou C, Pan F, Li Q, Ma S. 2015. MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma. Onco Targets Ther 8:3159–3167.
23. Lv ZC, Fan YS, Chen HB, Zhao DW. 2015. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumour Biol 36(3):1619–1625.
24. Markowitz SD, Bertagnolli MM. 2009. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460.
25. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. 2016. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271–289.
26. Mita Y, Yasuda Y, Sakai A, Yamamoto H, Toyooka S, Gunduz M, Tanabe S, Naomoto Y, Ouchida M, Shimizu K. 2010. Missense polymorphisms of PTPRJ and PTPN13 genes affect susceptibility to a variety of human cancers. J Cancer Res Clin Oncol 136(2):249–259.
27. Omerovic J, Clague MJ, Prior IA. 2010. Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. Biochem J 426(1):65–72.
28. Ortuso F, Paduano F, Carotenuto A, Gomez-Monterrey I, Bilotta A, Gaudio E, Sala M, Artese A, Vernieri E, Dattilo V, Iuliano R, Brancaccio D, Bertamino A, Musella S, Alcaro S, Grieco P, Perrotti N, Croce CM, Novellino E, Fusco A, Campiglia P, Trapasso F. 2013. Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation. ACS Chem Biol 8(7):1497–1506.
29. Ostman A, Hellberg C, Bohmer FD. 2006. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 6(4):307–320.
30. Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti N, Fusco A, Trapasso F, Iuliano R. 2013. Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J 280(2):401–412.
31. Paduano F, Ortuso F, Campiglia P, Raso C, Iaccino E, Gaspari M, Gaudio E, Mangone G, Carotenuto A, Bilotta A, Narciso D, Palmieri C, Agosti V, Artese A, Gomez-Monterrey I, Sala M, Cuda G, Iuliano R, Perrotti N, Scala G, Viglietto G, Alcaro S, Croce CM, Novellino E, Fusco A, Trapasso F. 2012. Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. ACS Chem Biol 7(10):1666–1676.
32. Palka HL, Park M, Tonks NK. 2003. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J Biol Chem 278(8):5728–5735.
33. Patnaik SK, Kannisto E, Yendamuri S. 2010. Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer or BEAS-2B normal lung cell lines does not alter phenotype. PLoS ONE 5(2):e9219.
34. Peyrou M, Ramadori P, Bourgoin L, Foti M. 2012. PPARs in liver diseases and cancer: Epigenetic regulation by microRNAs. PPAR Res 2012:757803.
35. Ruivenkamp C, Hermsen M, Postma C, Klous A, Baak J, Meijer G, Demant P. 2003. LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21. Oncogene 22(22):3472–3474.
36. Sacco F, Tinti M, Palma A, Ferrari E, Nardozza AP, Hooft van Huijsduijnen R, Takahashi T, Castagnoli L, Cesareni G. 2009. Tumor suppressor density-enhanced phosphatase-1 (DEP-1) inhibits the RAS pathway by direct dephosphorylation of ERK1/2 kinases. J Biol Chem 284(33):22048–22058.
37. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. 2008. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18(5):549–557.
38. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30.
39. Spring K, Fournier P, Lapointe L, Chabot C, Roussy J, Pommey S, Stagg J, Royal I. 2015. The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis. Oncogene 34(44):5536–5547.
40. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, Nuovo GJ, Fishel R, Croce CM. 2010. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA 107(49):21098–21103.
41. van Geel RM, Beijnen JH, Bernards R, Schellens JH. 2015. Treatment individualization in colorectal cancer. Curr Colorectal Cancer Rep 11(6):335–344.
42. Wan C, Han R, Liu L, Zhang F, Li F, Xiang M, Ding W. 2016. Role of miR-155 in fluorooctane sulfonate-induced oxidative hepatic damage via the Nrf2-dependent pathway. Toxicol Appl Pharmacol 295:85–93.
43. Yamakuchi M, Ferlito M, Lowenstein CJ. 2008. MiR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 105(36):13421–13426.
44. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9(11):798–809.
45. Zhang XF, Li KK, Gao L, Li SZ, Chen K, Zhang JB, Wang D, Tu RF, Zhang JX, Tao KX, Wang G, Zhang XD. 2015. MiR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPbeta. Oncotarget 6(6):4144–4158.
46. Zhang XF, Sun RQ, Jia YF, Chen Q, Tu RF, Li KK, Zhang XD, Du RL, Cao RH. 2016. Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents. Sci Rep 6:33204.
47. Zhao J, Feng Y, Yan H, Chen Y, Wang J, Chua B, Stuart C, Yin D. 2014. Beta-arrestin2/miR-155/GSK3beta regulates transition of 5′-azacytizine-induced Sca-1-positive cells to cardiomyocytes. J Cell Mol Med 18(8):1562–1570.